secwatch.observer — SEC 8-K summary
======================================

Issuer:     Summit Therapeutics Inc. (SMMT)
CIK:        0001599298
Form:       8-K
Filed at:   2026-09-14T12:37:42+00:00
Accession:  0001599298-26-000078
Event type: other_material
Sentiment:  positive
Materiality: 0.90
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ivonescimab HARMONi-2 shows OS benefit: HR 0.73, median OS 30.8 vs 22.6 months vs pembrolizumab
--------------------------------------------------------------------------------

- HARMONi-2 OS HR 0.73 (95% CI 0.57-0.95; p=0.009); median OS 30.8 vs 22.6 months.
- PD-L1 high subgroup HR 0.58; PD-L1 low HR 0.85; squamous HR 0.65; non-squamous HR 0.79.
- Serious TRAEs: 29.9% (ivonescimab) vs 21.6% (pembrolizumab); discontinuation 4.1% vs 5.0%.
- Summit's global Phase III HARMONi-7 (NCT06767514) targets 780 patients with PD-L1 high-expressing NSCLC.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1599298/000159929826000078/0001599298-26-000078-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1599298/000159929826000078/smmt-20260913.htm
  HTML page:      https://secwatch.observer/filing/0001599298-26-000078

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer